Predicting paravalvular leak after transcatheter mitral valve replacement using commercially available software modeling.


Journal

Journal of cardiovascular computed tomography
ISSN: 1876-861X
Titre abrégé: J Cardiovasc Comput Tomogr
Pays: United States
ID NLM: 101308347

Informations de publication

Date de publication:
Historique:
received: 31 10 2019
revised: 25 02 2020
accepted: 15 04 2020
pubmed: 16 5 2020
medline: 6 1 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

There is limited data identifying patients at risk for significant mitral regurgitation (MR) after transcatheter mitral valve replacement (TMVR). We hypothesized that software modeling based on computed tomography angiography (CTA) can predict the risk of moderate or severe MR after TMVR. 58 consecutive patients underwent TMVR at two institutions, including 31 valve-in-valve, 16 valve-in-ring, and 11 valve-in-mitral annular calcification. 12 (20%) patients developed moderate or severe MR due to paravalvular leak (PVL). The software model correctly predicted 8 (67%) patients with significant PVL, resulting in sensitivity of 67%, specificity 96%, positive predictive value 89%, and negative predictive value 86%. There was excellent agreement between CTA readers using software modeling to predict PVL (kappa 0.92; p < 0.01). On univariate analysis, CTA predictors of moderate or severe PVL included presence of a gap between the virtual valve and mitral annulus on the software model (OR 48; p < 0.01), mitral annular area (OR 1.02; p 0.01), and % valve oversizing (OR 0.9; p 0.01). On multivariate analysis, only presence of a gap on the software model remained significant (OR 36.8; p < 0.01). Software modeling using pre-procedural CTA is a straightforward method for predicting the risk of moderate and severe MR due to PVL after TMVR.

Sections du résumé

BACKGROUND BACKGROUND
There is limited data identifying patients at risk for significant mitral regurgitation (MR) after transcatheter mitral valve replacement (TMVR). We hypothesized that software modeling based on computed tomography angiography (CTA) can predict the risk of moderate or severe MR after TMVR.
METHODS METHODS
58 consecutive patients underwent TMVR at two institutions, including 31 valve-in-valve, 16 valve-in-ring, and 11 valve-in-mitral annular calcification. 12 (20%) patients developed moderate or severe MR due to paravalvular leak (PVL).
RESULTS RESULTS
The software model correctly predicted 8 (67%) patients with significant PVL, resulting in sensitivity of 67%, specificity 96%, positive predictive value 89%, and negative predictive value 86%. There was excellent agreement between CTA readers using software modeling to predict PVL (kappa 0.92; p < 0.01). On univariate analysis, CTA predictors of moderate or severe PVL included presence of a gap between the virtual valve and mitral annulus on the software model (OR 48; p < 0.01), mitral annular area (OR 1.02; p 0.01), and % valve oversizing (OR 0.9; p 0.01). On multivariate analysis, only presence of a gap on the software model remained significant (OR 36.8; p < 0.01).
CONCLUSIONS CONCLUSIONS
Software modeling using pre-procedural CTA is a straightforward method for predicting the risk of moderate and severe MR due to PVL after TMVR.

Identifiants

pubmed: 32409265
pii: S1934-5925(20)30137-4
doi: 10.1016/j.jcct.2020.04.007
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-499

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Michael F Morris (MF)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States. Electronic address: Michael.morris@bannerhealth.com.

Alejandro Pena (A)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States.

Aneesh Kalya (A)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States.

Abhishek C Sawant (AC)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States.

Kapildeo Lotun (K)

Division of Cardiology, Banner University Medical Center, Tucson, United States.

Timothy Byrne (T)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States; Abrazo Arizona Heart Hospital, United States.

H Kenith Fang (HK)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States.

Ashish Pershad (A)

Cardiovascular Institute, Banner University Medical Center, Phoenix, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH